SG11202109531UA - Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions - Google Patents

Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions

Info

Publication number
SG11202109531UA
SG11202109531UA SG11202109531UA SG11202109531UA SG11202109531UA SG 11202109531U A SG11202109531U A SG 11202109531UA SG 11202109531U A SG11202109531U A SG 11202109531UA SG 11202109531U A SG11202109531U A SG 11202109531UA SG 11202109531U A SG11202109531U A SG 11202109531UA
Authority
SG
Singapore
Prior art keywords
insertions
compounds
cancer cells
activity against
tumor activity
Prior art date
Application number
SG11202109531UA
Other languages
English (en)
Inventor
Jacqulyne Robichaux
John Heymach
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11202109531UA publication Critical patent/SG11202109531UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202109531UA 2019-03-29 2020-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions SG11202109531UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962826758P 2019-03-29 2019-03-29
PCT/US2020/025478 WO2020205632A1 (en) 2019-03-29 2020-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions

Publications (1)

Publication Number Publication Date
SG11202109531UA true SG11202109531UA (en) 2021-09-29

Family

ID=72666271

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109531UA SG11202109531UA (en) 2019-03-29 2020-03-27 Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions

Country Status (13)

Country Link
US (1) US20220175778A1 (https=)
EP (1) EP3946632A4 (https=)
JP (1) JP7700043B2 (https=)
KR (1) KR20210145161A (https=)
CN (1) CN113766955A (https=)
AU (1) AU2020256119A1 (https=)
BR (1) BR112021019376A2 (https=)
CA (1) CA3132834A1 (https=)
IL (1) IL286576A (https=)
MX (1) MX2021011925A (https=)
PH (1) PH12021552110A1 (https=)
SG (1) SG11202109531UA (https=)
WO (1) WO2020205632A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3956035A4 (en) * 2019-04-17 2023-01-25 Board of Regents, The University of Texas System ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS
PY21113397A (es) * 2020-12-29 2022-10-12 Spectrum Pharmaceuticals Inc Tratamiento para tumores sólidos malignos
CA3264494A1 (en) * 2022-08-09 2024-02-15 Heligenics Inc. METHOD FOR EVALUATING THE CLINICAL RELEVANCE OF A GENETIC VARIANCE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101217526B1 (ko) * 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
KR101317809B1 (ko) * 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
IN2014DN05803A (https=) * 2011-12-14 2015-05-15 Univ Texas
KR20190015360A (ko) * 2016-05-31 2019-02-13 네스텍 소시에테아노님 Her2 및 her3 경로 아형 분류를 기반으로 한, 유방암 환자에 대한 약물 치료법의 선택 방법
KR102771603B1 (ko) * 2016-11-17 2025-02-24 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
MX2021007554A (es) * 2018-12-21 2021-08-11 Univ Texas Terapia de combinacion para el tratamiento de cancer.
KR102477643B1 (ko) * 2019-05-09 2022-12-13 주식회사 엘지에너지솔루션 전기화학소자용 분리막 및 이를 포함하는 전기화학소자

Also Published As

Publication number Publication date
WO2020205632A1 (en) 2020-10-08
EP3946632A4 (en) 2023-01-04
JP2022527499A (ja) 2022-06-02
MX2021011925A (es) 2021-11-03
WO2020205632A8 (en) 2021-10-14
US20220175778A1 (en) 2022-06-09
CA3132834A1 (en) 2020-10-08
PH12021552110A1 (en) 2022-06-06
EP3946632A1 (en) 2022-02-09
IL286576A (en) 2021-12-01
JP7700043B2 (ja) 2025-06-30
CN113766955A (zh) 2021-12-07
BR112021019376A2 (pt) 2021-12-07
KR20210145161A (ko) 2021-12-01
AU2020256119A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
IL286742A (en) Compounds with antitumor activity against cancer cells carrying insertions in exon 20 of her2 or egfr
IL286576A (en) Compounds with antitumor activity against cancer cells containing exon 21 her2 insertions
CA198339S (en) Travel organizer
MX2019005834A (es) Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2.
IL277373A (en) Compounds with antitumor activity against cancer cells with a mutation in exon 19 of HER2
MX393599B (es) Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco
ZA202102745B (en) Anti-ptk7 immune cell cancer therapy
SG10201811701YA (en) Non-human animals having a humanized a proliferation-inducing ligand gene
GB202110535D0 (en) Stabilized Crispr complexes
EP3773650A4 (en) Neoadjuvant cancer treatment
CA207042S (en) Ventilation shield
GB2627905B (en) Cordycepin-based derivatized compound with anti-tumor effect
MX2018006776A (es) Usos de pirimido-piridazinonas para tratar el cancer.
CA211787S (en) Roller shield
EP3983063A4 (en) RADIATION SHIELDING FOR BRACHYTHERAPY
GB201918313D0 (en) Cells for treating cancer
MX2009010954A (es) Actividad antitumoral de temsirolimus en cancer celular renal papilar.
WO2016081589A3 (en) 13-cis-ramba retinamides that degrade mnks for treating cancer
GB202211202D0 (en) Headphones with EMF shielding material
CA3269203A1 (en) Compounds with anti-tumor activity against kras mutated tumors
WO2015057737A3 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF VprBP-RELATED CANCERS
IL316821A (en) Cancer treatment with NUC-7738
GB202115108D0 (en) 3D cancer cells
HK40076174A (en) Cells for treating cancer
GB202316527D0 (en) Computer-implemented distributed processing scheme